Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she continues to defend the drug’s data against skepticism.

Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for the treatment of metastatic pancreatic cancer.

Baxter has initiated a recall of two products because of particulate matter and Vitruvias Therapeutics has recalled one lot of thyroid tablets because of their potential to be “superpotent.”

As the leadership vacuum at the top of the FDA looks poised to close with President Donald Trump’s nominee pick for a replacement commissioner, the agency is reportedly weighing whether to add two new deputy posts under that role.

The healthcare conglomerate ,which ranks eighth on the Fortune 500 list, is set to envelope privately held Precision Medicine Group into its oncology branch as part of an ongoing effort to grow it’s high-margin cancer and biopharma businesses.

Courts in Maryland and Washington, D.C., have rejected separate lawsuits by Merck and AstraZeneca against the Centers for Medicare & Medicaid Services’ drug price negotiation program.